# Quercetin in Coronary Artery By-pass Surgery

Study · id `cardio:ct-nct04907253` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04907253](<https://clinicaltrials.gov/study/NCT04907253>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04907253

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT04907253. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-04 (actual); primary completion 2023-12-01 (actual). Results posted on 2026-04-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT04907253, source copy `cardio:ctgov-nct04907253-2026-04-15`, retrieved 2026-10-26)
- Started: 2021-06-04 (actual) (ClinicalTrials.gov record NCT04907253, source copy `cardio:ctgov-nct04907253-2026-04-15`, retrieved 2026-10-26)
- Primary completion: 2023-12-01 (actual) (ClinicalTrials.gov record NCT04907253, source copy `cardio:ctgov-nct04907253-2026-04-15`, retrieved 2026-10-26)
- Completion: 2025-05-16 (actual) (ClinicalTrials.gov record NCT04907253, source copy `cardio:ctgov-nct04907253-2026-04-15`, retrieved 2026-10-26)
- Results first posted: 2026-04-15 (ClinicalTrials.gov record NCT04907253, source copy `cardio:ctgov-nct04907253-2026-04-15`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT04907253, source copy `cardio:ctgov-nct04907253-2026-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04907253-2026-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Quercetin in Coronary Artery By-pass Surgery
- Acronym: Q-CABG
- Condition: Coronary Artery Disease
- Intervention (Drug): Quercetin
- Intervention (Drug): Placebo
- Lead sponsor: Montreal Heart Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Montreal Heart Institute (`cardio:org-montreal-heart-institute`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients (`cardio:pubmed-40375481`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7b32af5844baaab1c7a06c3ca0ca4fb76787a33e6cbef132b275f2cd91af0516
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
